Prostate Cancer

Peritoneal carcinomatosis happens when cancer cells from the ovary spread to the peritoneum. It is often present in advanced or recurrent epithelial ovarian cancers. Peritoneal cancer is a rare, advanced cancer that develops in the peritoneum. It may begin in the peritoneum, a condition doctors call primary peritoneal cancer, or the spread of malignant cells from tumors in other organs like the ovaries may cause it. Doctors refer to the condition as peritoneal carcinomatosis when it occurs due to the spread of malignant cells. Whether peritoneal cancer originates from the peritoneum or has spread from somewhere else, doctors consider it an advanced form of cancer. People with this illness have a poor outlook. This article explores the link between peritoneal carcinomatosis and ovarian cancer. We also discuss who is at risk of the condition, its symptoms, causes, and more. The peritoneum is a thin layer of tissue made of epithelial cells. The parietal peritoneum lines the abdominal wall

Patients with high-risk prostate cancer appeared to derive benefit from androgen deprivation therapy given for a minimal duration of over 18 months plus external beam radiotherapy. A cohort study found that the optimal minimum duration for androgen deprivation therapy (ADT) plus high-dose external beam radiotherapy (EBRT) was more than 18 months for a significant impact in patients with high-risk prostate cancer. However, EBRT plus brachytherapy was found to yield benefit at 18 months or less, according to a study published in JAMA Oncology . A total of 2935 patients were included in the study population from 3 different cohort studies. The minimum duration of thresholds found through a cubic spline analysis was 26.3 months (95% CI, 25.4-36.0) for EBRT and 12 months (95% CI, 4.9-36.0) for EBRT plus brachytherapy to have an improved effect on distant metastases-free survival (DMFS). The phase 3 RADAR study (NCT00193856) found patients who were treated with ADT plus EBRT for a prolong

Could that small bump be a sign of breast cancer? Probably not—but here's what it might mean. March 21, 2022 Medical Reviewer March 21, 2022 Medical Reviewer On this page You're taking your bra off at the end of the day when you notice it: a small, red spot on your breast. It looks like a pimple, but you're not sure—is breast acne even a thing? Or could this be a sign of something more serious, like breast cancer? Let's cut to the chase for a little peace of mind: Pimple-like marks on the breast are usually just that—pimples. "We often say, 'common things are common,'" says Danika Forgach, M.D., an OB-GYN at UCHealth Women's Care Clinic in Greeley, CO. So what might be causing the pimples on your breast? Let's take a deeper look at possible explanations and explore whether red spots on the breast are ever symptoms of breast cancer. Breast Acne Causes Acne—like the little dots your get on your back or face—is the most likely culprit for the spot

Hives (urticaria) may appear as pink-red bumps, or patches on your skin, and are very itchy. They are often signs of an allergic reaction but can also be idiopathic, meaning the cause is unknown. While hives tend to disappear within hours, they may reoccur. They can show up anywhere on the body that has come into contact with irritating substances, including the breast area. It's important to have a doctor check any rashes on the breasts or the areola, and to not quickly assume it's just hives. Aside from hives, other possible rashes or skin conditions that can occur around the breasts include: Let's go over how to evaluate whether your rash is due to hives or another possible cause, and when you should see a doctor for further evaluation. Hives are primarily caused by our body's release of the chemical histamine, which is also generated in allergic reactions. According to the American Academy of Dermatology (AAD), here are some common allergens and environmental factor

The ability and track record of a surgeon is of utmost importance when a patient with prostate cancer is selecting the team that may operate on them and potentially remove the organ, according to an expert. Dr. Ganesh V. Raj, The Dr. Paul Peters Chair in Urology at UT Southwestern Medical Center in Dallas, Texas, recently discussed the role of surgery and active surveillance for prostate cancer during CURE®'s Educated Patient® Prostate Cancer Summit. Moreover, Raj highlighted how decisions to treat are made and how advances have been made over the years to ensure that patients retain their ability to get an erection and don't experience incontinence. Is the Prostate Cancer Localized? Before a treatment decision is made, providers assess if the disease is localized to the prostate or if it has metastasized — or spread to other nearby organs or lymph nodes. Raj explained that if the cancer is localized to the prostate, then surgery, radiation or even active surveillance (routine

Share on Pinterest A combination approach to prostate cancer treatment may be the best way forward, according to new research. Image credit: MirageC/Getty Images. Prostate cancer is a type of cancer that can lead to death. The exact treatment for prostate cancer will depend on the person and the cancer's severity. Researchers are still working to improve treatment options for prostate cancer. A recent study found that the combined use of three different therapies improved the survival rate among men with prostate cancer. Cancer impacts people all over the world. Experts are constantly evaluating how different treatments can eliminate or slow the spread of cancer Each type of cancer is different, leading to the development of various treatment and detection methods. A recent study that appears in The Lancet found that a specific combined treatment therapy may improve the survival rate for men with prostate cancer. Prostate cancer is one of the most common types of cancer among men.

Radiotherapeutic treatment options for patients with prostate cancer have continue to evolve to become more patient-friendly, according to Walter J. Curran Jr, MD, FACR, FASCO. Furthermore, although radiotherapy has existed as a prostate cancer treatment option for more than a century, in the past 100 years, this treatment strategy has evolved from a crude method to a potentially curative therapy that can be administered within 2 weeks, he noted. Curran, professor emeritus with the Department of Radiation Oncology at Emory University School of Medicine and the 2021 Giants of Cancer Care® award winner for radiation oncology, recently delivered the Giants of Cancer Care® keynote address during the  15th Annual  Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies, during which he provided a quick glance of the treatment landscape for this specialty and future directions for the field. 1 Brachytherapy (BT) was the first type of therapeutic rad

Squamous cell carcinoma (SCC) is the second most prominent form of skin malignancy. It occurs most frequently in older males with fair skin complexion that have extensive sun exposure most commonly in their childhood. The metastatic presentation of SCC is rare and is most common in the lung. In this paper, we present the unique case of a 73-year-old patient with sarcomatoid squamous cell carcinoma in their posterior neck that metastasized to the brain. Introduction Cutaneous squamous cell carcinoma (cSCC) represents one of the most prominent types of skin cancer alongside basal cell carcinoma and melanoma [1]. Pathologically, ultraviolet (UV) radiation is well accepted as the primary driver of cutaneous neoplasms via its modulation of the p53 gene [2]. Histologically, squamous cell carcinoma (SCC) is characterized through the presence of hyperkeratosis alongside prominent acanthosis, thickening of the rete ridges, irregular nests, and sheets of keratinocytes invading the derm

Investigators reported that individuals who completed 10 cycles of lurbinectedin and doxorubicin who then switched to lurbinectedin as a monotherapy tended to have maintained or improved tumor response. Individuals with relapsed small cell lung cancer (SCLC) who completed 10 cycles of lurbinectedin (Zepzelca; Jazz Pharmaceuticals) and doxorubicin (Adriamycin; Pfizer) combination and switched to lurbinectedin as a monotherapy tended to have a tumor response that was maintained or improved, according to a session at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting. Lurbinectedin, a selective inhibitor of oncogenic transcription, had received accelerated approval from the FDA in June 2020 as a monotherapy for adults with metastatic SCLC with disease progression on or after platinum-based chemotherapy. Data from the phase 3 ATLANTIS trial that showed the overall response rate (ORR) to this regimen in 105 trial participants was 35.2% with the duration of response (DOR) a

Lupron Depot and Lupron Depot-Ped are a type of hormone therapy. This medication belongs to a group of drugs called gonadotropin-releasing hormone (GnRH) agonists. GnRH agonists work by activating the pituitary gland in your brain to release certain hormones. In turn, these hormones cause your reproductive system to release a surge of sex hormones. (These are mainly testosterone in males* and estrogen in females.*) This surge signals your body to stop making the sex hormones. Ultimately, in males, Lupron Depot causes the testicles to stop making testosterone. And in females, the drug causes the ovaries to stop making estrogen and progesterone. Lupron Depot and Lupron Depot-Ped are used to treat certain conditions that may improve when the body stops making these hormones. These conditions are described below. * In this article, we use the terms "male" and "female" to refer to someone's sex assigned at birth. For information about the difference between sex and

Abstract Evaluation of the greater wings of the sphenoid bone is difficult because of the complex anatomy and the wide range of diseases that can affect this area, but a systematic approach to cross-sectional imaging can help in the diagnosis and reporting of these lesions. The greater wings of the sphenoid bone (GWS) comprise the components of the sphenoid bone that make up most of the posterior orbital wall and form the anterior and medial parts of the floor of the middle cranial fossa. Many important skull base foramina, which transmit vital neurovascular structures, are present in these paired wings on either side of the central body of the sphenoid bone. A wide variety of diseases can affect the GWS, ranging from benign osseus lesions to malignant primary and secondary bone abnormalities. The